<ul>
<li>Shanghai Henlius unit Shanghai Henlius Biologics cleared a Shanghai regulator GMP inspection for HANBEIYOU pertuzumab injection production lines.  *      Inspection covered drug substance east line, drug product line, packaging line at the Songjiang First Plant in Shanghai.     *      Result supports commercial production eligibility in mainland China for HANBEIYOU under China GMP requirements. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260617-12206277), on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

02696

<p>Shanghai Henlius Biologics passed a China GMP inspection for its HANBEIYOU (pertuzumab injection) production lines. The inspection covered drug substance, product, and packaging lines at the Songjiang First Plant in Shanghai. This result confirms the company's eligibility for commercial production of HANBEIYOU in mainland China under current GMP requirements.</p>

Henlius unit Shanghai Henlius Biologics passes China GMP inspection for HANBEIYOU production lines